PRMA Consulting Leader Discusses the Rapidly Increasing Influence of ICER’s Value Access Frameworks
Senior Principal at PRMA Consulting Emily Coriale discusses how value assessments put forth by the Institute for Clinical and Economic [...]
ICER Meets With FDA, EMA, and FDA to Discuss RWE Procedures
In a recent meeting, members of the Institute for Clinical and Economic Review (ICER), the Food and Drug Administration (FDA), [...]
New Report Estimates 30% in CMS Drug Savings Using Domestic Reference Pricing Model
A new report estimates that Medicare could have seen savings as high as 30% had a domestic reference pricing approach [...]
ICER VP Discusses Adding the Patient Voice to Value Assessments
Vice President of Patient Engagement at the Institute for Clinical and Economic Review (ICER) Yvette Venable highlights the importance of [...]
ICER Publishes Draft Evidence Report on Asthma Drug; Register Now for October Webinar
The Institute for Clinical and Economic Review (ICER) has published its Draft Evidence Report for severe asthma drug tezepelumab. The [...]
ICER Releases Draft Evidence Report for AstraZeneca’s Asthma Drug
The Institute for Clinical and Economic Review (ICER) recently published its draft evidence report for asthma drug tezepelumab. The monoclonal [...]
Apply Today for EMAUD’s International Market Access Program
Interested medical affairs (MA) and market access professionals are invited to apply for the European Market Access University Diploma (EMAUD). [...]
ICER Whitepaper Proposes Improvements to the FDA’s Accelerated Approval Pathway
The Institute for Clinical and Economic Review (ICER) has released a whitepaper proposing policy reforms that would improve the Food and Drug [...]
ICER’s Draft Evidence for Hypertrophic Cardiomyopathy Drug Now Available
The Institute for Clinical and Economic Review (ICER) has released its draft evidence report for mavacamten, a drug intended for use [...]
ICER’s RWE Study of Hereditary Angioedema Treatments Provides New Insight
The Institute for Clinical and Economic Review (ICER) recently published results from a real world evidence study (RWE) assessing the [...]
Aduhelm Approval Prompts Discussions on Reforming the FDA’s Accelerated Approval Pathway
The Food and Drug Administration (FDA)’s contentious approval of Biogen’s Aduhelm has prompted discussions on how the accelerated approval process [...]
ICER to Evaluate Value and Efficacy of Five COVID-19 Treatments
The Institute for Clinical and Economic Review (ICER) announced it will carry out assessments for five drugs used to treat [...]
Aetion Researchers Discuss ICER’s Reassessment of Drugs Receiving Accelerated FDA Approval Using RWE
The Institute for Clinical and Economic Review (ICER) recently published findings from a pilot study that used real world evidence [...]
ICER Revises 2018 Hereditary Angioedema Report Using RWE, Recommends Up to 75% Price Reduction
Researchers at the Institute for Clinical and Economic Review (ICER), Aetion, and the University of Washington collaborated to determine how [...]
Register Now for ICER’s Tuesday Webinar on Myasthenia Gravis Therapies
The Institute for Clinical and Economic Review (ICER) will hold a webinar on Tuesday, August 24th at 2:00 PM ET. [...]
Novartis and University of California-Berkeley Researchers Estimate $93 Billion Wasted Yearly Across Healthcare Stakeholders, Propose Value-Based Pricing System
Researchers at the University of California-Berkeley and Novartis note that $93 billion is wasted yearly in addressing healthcare utilization management, [...]
ICER’s Final Evidence Report on Biogen’s Aduhelm Released, Notes Insufficient Clinical Evidence for Overly Expensive Alzheimer’s Drug
The Institute for Clinical and Economic Review (ICER) has published its Final Evidence Report on aducanumab, Biogen’s infamous Alzheimer’s drug. [...]
ICER Announces Positive Early Results in Draft Evidence Report for Two Myasthenia Graves Therapies
The Institute for Clinical and Economic Review (ICER) has published its Draft Evidence Report on two drugs, eculizumaband efgartigimod, used [...]
Costly Oncology Drugs Face ICER Scrutiny and Calls for Value-Based Pricing
Novel drugs used in cancer treatment, including chimeric antigen receptor (CAR)-T cell therapies, are increasing in popularity. However, their cost [...]
ICER Proposes Legislative Mechanisms to Keep Prices Low for Drugs Receiving FDA’s Accelerated Approval Designation
The Institute for Clinical and Economic Review (ICER) suggests enacting federal legislation that would keep prices low for drugs receiving [...]
Will Senate Finance Committee Chair Use Domestic Reference Pricing in Prescription Drug Negotiation Plan?
Allowing Medicare to negotiate prescription drug costs is one method of reducing healthcare costs. Now, Senate Finance Committee Chair Ron [...]
ICER Considers Fair Access Principles as Aduhelm Price Continues to Incense Critics
The Institute for Clinical and Economic Review (ICER) recently published its protocol detailing how it will gauge access to prescription [...]
Biogen’s Aduhelm Price Tag Too High Says ICER
The Institute for Clinical and Economic Review (ICER) published a revised report on Biogen’s Aduhelm. The drug is designed for [...]
ICER Finds Insufficient Clinical Benefit for Controversial Alzheimer’s Drug in Revised Report and Calls for Price Reduction Ahead of CTAF meeting
The Institute for Clinical and Economic Review (ICER) has issued a revised evidence report on Biogen’s Aduhelm, or aducanumab. ICER [...]
New ICER Webinar Series on RWD Case Studies; First Webinar on Alzheimer’s Disease Evidence Report
The Institute for Clinical and Economic Review (ICER) will begin a webinar series highlighting findings from recent draft reports and provide [...]